Biosimilar Development News

  1. Celltrion And Rani Therapeutics Partner On Development Of Oral Monoclonal Antibody Treatment 1/9/2023

    Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar.

  2. Coherus Agrees To Acquire Exclusive U.S. Commercial Rights To Eylea® Biosimilar FYB203 From Klinge Biopharma 1/9/2023

    Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH (Klinge Biopharma) for the exclusive commercialization rights to FYB203, a biosimilar candidate to Eylea® (aflibercept), in the United States.

  3. Alvotech And Teva Announce Acceptance Of U.S. Biologics License Application For AVT04, A Proposed Biosimilar To Stelara® (ustekinumab) 1/6/2023

    Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT04, Alvotech’s proposed biosimilar to Stelara® (ustekinumab), which is prescribed to treat a variety of inflammatory conditions.

  4. Lannett Provides Development Update On Biosimilar Insulin Products 1/4/2023

    Lannett Company, Inc. (NYSE: LCI) today provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products. Lannett is developing both products with its strategic alliance partner, the HEC Group of companies (HEC).

  5. Samsung Bioepis Announces Health Canada Approval Of Citrate-Free High-Concentration Of HUMIRA7® 1 Biosimilar (adalimumab; SB5) 1/3/2023

    Samsung Bioepis Co., Ltd. today announced that Health Canada has approved HADLIMA™ (also known as SB5) - a citrate-free, high concentration (40 mg/0.4 ML) formulation of biosimilar referencing HUMIRA® (adalimumab).

  6. Global Biosimilar Market To Gather $83,836.40M By 2028, Growing At A CAGR Of 24.90% In The 2021-2028 Timeframe [170-Pages] | Issued By Research Dive 1/3/2023

    According to the latest report published by Research Dive, the global biosimilar market is expected to gather a revenue of $83,836.40 million by 2028, growing at a healthy CAGR of 24.90% in the 2021-2028 timeframe.

  7. Hikma And Celltrion Healthcare Sign New Exclusive Licensing Agreement For Vegzelma For The Middle East And North Africa Region 1/3/2023

    Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreement with Celltrion Healthcare Co., Ltd, a global biopharmaceutical company, for Vegzelma (CT-P16, bevacizumab).

  8. Alteogen Enters Into An Exclusive License Agreement To Develop And Commercialize Biosimilar Products Enabled By Alteogen’s Hybrozyme Technology 1/2/2023

    Alteogen Inc. announced today that the company has entered into an exclusive license agreement with Sandoz AG. Under the terms of the agreement, Sandoz will acquire the world-wide rights to use ALT-B4, Alteogen’s novel hyaluronidase derived utilizing Hybrozyme™ Technology, to develop and commercialize a subcutaneous version of a Sandoz biosimilar product.

  9. Healthcare Analytical Testing Services Global Market Report 2022: Growing Focus On Analytical Testing Of Biologics & Biosimilars Boosts Sector 12/28/2022

    The "Healthcare Analytical Testing Services Market by Type (Biomarker Testing, Stability Testing, Raw Material Testing, Batch-release Testing, Cleaning Validation, End User (Pharmaceutical Companies, Medical Device Companies, CRO) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

  10. Cell Line Development Services Global Market Report 2022: Industry To Reach $2.09B By 2030 With Increasing Demand For Biologics And Biosimilars Driving Growth 12/28/2022

    The "Cell Line Development Services Global Market - Forecast To 2030" report has been added to ResearchAndMarkets.com's offering.